Figure 1.
![Figure 1. EFS according to Rituximab [R] administration, in (A) low-grade and (B) intermediate/high-grade, B-cell lymphoma patients treated with a HDS program](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/108/11/10.1182_blood.v108.11.207.207/3/207.jpeg?Expires=1752464314&Signature=GHNXY4B4ODVS3PqvlT1LuYfnDcsXlsOcovkvtUe9eMOK1w-PQ7Wp4V-HlmUd~kg2w8aHemQNUCOIETnz1jEyOJYTJbnAvv7BojdPnpJ0TR-nYd-fayT25NAIoMbQbj3VLq5PitYmQcb2QgdIoA5Ys71v2mdWkjUlecD0eNuRIHj7DIlr6pAA20Tvu2Ay7sG20e1gGD~YhK1uyeB805M36rIcj6dCpm3HbBmC0iAI~KX4Kewwo6bBiMPYiPLodjsuKoRcE7D1g9Ko34tjcV~eKc1fXzjaJktupaSDoG0NEMrqvKWxpwlpbFB6h7C7rW1tGx4KFFwAjLKMAlXyivzglA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
EFS according to Rituximab [R] administration, in (A) low-grade and (B) intermediate/high-grade, B-cell lymphoma patients treated with a HDS program
EFS according to Rituximab [R] administration, in (A) low-grade and (B) intermediate/high-grade, B-cell lymphoma patients treated with a HDS program
